Shenzhen New Industries Biomedical Engineering Co., Ltd.
Simbolo: 300832.SZ
SHZ
73.76
CNYPrezzo di mercato oggi
33.6007
Rapporto P/E
1.4197
Rapporto PEG
57.95B
Capitalizzazione MRK
- 0.01%
Rendimento DIV
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832-SZ) Bilanci finanziari
Stato patrimoniale
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 13023.92 | 3404.2 | 3297.1 | 3424.1 | ||||||||||||
balance-sheet.row.short-term-investments | 9611.54 | 2356 | 2813.7 | 2806.5 | ||||||||||||
balance-sheet.row.net-receivables | 2814.17 | 712.4 | 506.6 | 314.3 | ||||||||||||
balance-sheet.row.inventory | 3674.32 | 916.8 | 839.3 | 645.4 | ||||||||||||
balance-sheet.row.other-current-assets | 915.34 | 30.5 | 179.3 | 113.4 | ||||||||||||
balance-sheet.row.total-current-assets | 20427.76 | 5064 | 4822.4 | 4497.1 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 5639.13 | 1446.6 | 1325.5 | 1134.3 | ||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.intangible-assets | 679.06 | 169.5 | 172.5 | 94.6 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 679.06 | 169.5 | 172.5 | 94.6 | ||||||||||||
balance-sheet.row.long-term-investments | -1302.33 | 1347.8 | -2456 | -2669.6 | ||||||||||||
balance-sheet.row.tax-assets | 142.52 | 37.9 | 22.9 | 12.1 | ||||||||||||
balance-sheet.row.other-non-current-assets | 6182.77 | 156.7 | 3127.4 | 3066.9 | ||||||||||||
balance-sheet.row.total-non-current-assets | 11341.15 | 3158.5 | 2192.2 | 1638.4 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 31768.91 | 8222.5 | 7014.6 | 6135.5 | ||||||||||||
balance-sheet.row.account-payables | 560.85 | 127 | 176.7 | 171.4 | ||||||||||||
balance-sheet.row.short-term-debt | 6.4 | 1.7 | 1.3 | 1.4 | ||||||||||||
balance-sheet.row.tax-payables | 473.17 | 120.4 | 79.5 | 69.9 | ||||||||||||
balance-sheet.row.long-term-debt-total | 11.5 | 3.5 | 0.9 | 0.9 | ||||||||||||
Deferred Revenue Non Current | 88.86 | 33.1 | 5.8 | 6.6 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 183.64 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 675.59 | 371.3 | 297 | 3.7 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 250.94 | 53.6 | 31.1 | 15.6 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 11.5 | 3.5 | 0.9 | 0.9 | ||||||||||||
balance-sheet.row.total-liab | 2477.35 | 645 | 615.1 | 523.5 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 3142.88 | 785.7 | 786.1 | 786.7 | ||||||||||||
balance-sheet.row.retained-earnings | 18976.04 | 4980.7 | 3874.3 | 3108.5 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 4686.62 | 551.5 | 496.7 | 453.4 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 2452.96 | 1226.5 | 1242.4 | 1263.4 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 29258.5 | 7544.4 | 6399.5 | 5612 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 31768.91 | 8222.5 | 7014.6 | 6135.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-equity | 29258.5 | 7544.4 | 6399.5 | 5612 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 31768.91 | - | - | - | ||||||||||||
Total Investments | 8309.21 | 3703.7 | 357.6 | 136.9 | ||||||||||||
balance-sheet.row.total-debt | 17.9 | 5.2 | 2.2 | 2.2 | ||||||||||||
balance-sheet.row.net-debt | -3394.47 | -1043.1 | -481.2 | -615.3 |
Rendiconto finanziario
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1724.81 | 1653.7 | 1327.9 | 973.7 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 21.32 | 179.2 | 116.5 | 97 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | 4.8 | 3.2 | 18.3 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | -688 | -80.7 | 93.9 | ||||||||||||
cash-flows.row.change-in-working-capital | -413.67 | -329.7 | -304.8 | -354 | ||||||||||||
cash-flows.row.account-receivables | -277.18 | -277.2 | -240.2 | -154.7 | ||||||||||||
cash-flows.row.inventory | -136.49 | -136.5 | -229.9 | -227.7 | ||||||||||||
cash-flows.row.account-payables | 0 | 84 | 162.1 | 10 | ||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 3.2 | 18.3 | ||||||||||||
cash-flows.row.other-non-cash-items | 254.94 | 678.2 | -99.6 | -55.6 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1587.4 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -369.71 | -322.2 | -403.2 | -342.9 | ||||||||||||
cash-flows.row.acquisitions-net | 0.06 | 0.1 | 0.7 | 0.2 | ||||||||||||
cash-flows.row.purchases-of-investments | -6550.59 | -7509.5 | -10196.3 | -9617.8 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 6228.76 | 7461 | 10010.1 | 9036 | ||||||||||||
cash-flows.row.other-investing-activites | -144.26 | 0 | -5 | 0 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -696.49 | -370.6 | -593.7 | -924.6 | ||||||||||||
cash-flows.row.debt-repayment | 0 | -16.3 | -4.1 | -3.6 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 25.7 | 0 | ||||||||||||
cash-flows.row.common-stock-repurchased | -32.57 | 0 | -21.6 | 0 | ||||||||||||
cash-flows.row.dividends-paid | -549.64 | -550 | -471.8 | -413.4 | ||||||||||||
cash-flows.row.other-financing-activites | 567.33 | 1.8 | -25.7 | 129.6 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -568.42 | -568.6 | -497.4 | -287.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 5.16 | 8.7 | -9.1 | -14 | ||||||||||||
cash-flows.row.net-change-in-cash | 327.77 | 564.8 | -137.9 | -452.8 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 3410.79 | 1048.3 | 478.1 | 616 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 3083.02 | 483.4 | 616 | 1068.8 | ||||||||||||
cash-flows.row.operating-cash-flow | 1587.4 | 1498.1 | 962.4 | 773.2 | ||||||||||||
cash-flows.row.capital-expenditure | -369.71 | -322.2 | -403.2 | -342.9 | ||||||||||||
cash-flows.row.free-cash-flow | 1217.69 | 1175.9 | 559.2 | 430.3 |
Riga del conto economico
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 4067.04 | 3914.4 | 3047 | 2545.4 | ||||||||||||
income-statement-row.row.cost-of-revenue | 1085.44 | 1170.3 | 906.2 | 734.3 | ||||||||||||
income-statement-row.row.gross-profit | 2981.6 | 2744.1 | 2140.8 | 1811.1 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 375.54 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 58.35 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 664.42 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | -2.21 | -2.1 | -41.4 | 109.1 | ||||||||||||
income-statement-row.row.operating-expenses | 1142.73 | 1006 | 772.6 | 723.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 2228.16 | 2176.3 | 1678.8 | 1458.2 | ||||||||||||
income-statement-row.row.interest-income | 12.68 | 15.4 | 5.4 | 3.7 | ||||||||||||
income-statement-row.row.interest-expense | 0.42 | 0.4 | 0.3 | 0.2 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 664.42 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 63.21 | 155 | -2.4 | -1.9 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | -2.21 | -2.1 | -41.4 | 109.1 | ||||||||||||
income-statement-row.row.total-operating-expenses | 63.21 | 155 | -2.4 | -1.9 | ||||||||||||
income-statement-row.row.interest-expense | 0.42 | 0.4 | 0.3 | 0.2 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 34.5 | 179.2 | 112.8 | 68.8 | ||||||||||||
income-statement-row.row.ebitda-caps | 1981.22 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 1910.83 | 1738.1 | 1503.6 | 1137.4 | ||||||||||||
income-statement-row.row.income-before-tax | 1974.05 | 1893.1 | 1501.2 | 1135.5 | ||||||||||||
income-statement-row.row.income-tax-expense | 249.24 | 239.4 | 173.3 | 161.8 | ||||||||||||
income-statement-row.row.net-income | 1724.81 | 1653.7 | 1327.9 | 973.7 |
Domande frequenti
Che cos'è Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) totale attivo?
Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) il totale delle attività è 8222488843.000.
Qual è il fatturato annuo dell'impresa?
Il fatturato annuo è 2034791253.000.
Qual è il margine di profitto dell'azienda?
Il margine di profitto dell'azienda è 0.733.
Qual è il flusso di cassa libero dell'azienda?
Il flusso di cassa libero è 1.550.
Qual è il margine di profitto netto dell'impresa?
Il margine di profitto netto è 0.424.
Qual è il fatturato totale dell'azienda?
Le entrate totali sono 0.470.
Che cos'è il Shenzhen New Industries Biomedical Engineering Co., Ltd. (300832.SZ) utile netto (reddito netto)?
L'utile netto (reddito netto) è 1653653244.000.
Qual è il debito totale dell'azienda?
Il debito totale è 5179720.000.
Qual è il numero di spese operative?
Le spese operative sono 1006019450.000.
Qual è la cifra della liquidità aziendale?
La liquidità aziendale è 1028408740.000.